Symbicort brought in worldwide sales of $2.7 ... has been given the nod for use by the NHS in England after an earlier rejection. Regulators have started reviews of GSK's depemokimab, aiming ...

The cap is effective June 1 and will apply to the company’s entire range of inhaler products used to treat asthma and chronic obstructive pulmonary disease, including inhalers Symbicort ...